CN100369899C - 具有抗癌活性的取代的吲唑 - Google Patents

具有抗癌活性的取代的吲唑 Download PDF

Info

Publication number
CN100369899C
CN100369899C CNB038058731A CN03805873A CN100369899C CN 100369899 C CN100369899 C CN 100369899C CN B038058731 A CNB038058731 A CN B038058731A CN 03805873 A CN03805873 A CN 03805873A CN 100369899 C CN100369899 C CN 100369899C
Authority
CN
China
Prior art keywords
indazole
benzsulfamide
phenyl
methyl sulphonyl
methylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038058731A
Other languages
English (en)
Chinese (zh)
Other versions
CN1642922A (zh
Inventor
D·达穆尔
J-C·卡里
P·内梅切克
C·泰里耶
F·纳尔迪
B·菲洛什
M-P·谢里耶
D·贝扎尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of CN1642922A publication Critical patent/CN1642922A/zh
Application granted granted Critical
Publication of CN100369899C publication Critical patent/CN100369899C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
CNB038058731A 2002-03-11 2003-03-07 具有抗癌活性的取代的吲唑 Expired - Fee Related CN100369899C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0202996A FR2836914B1 (fr) 2002-03-11 2002-03-11 Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
FR02/02996 2002-03-11

Publications (2)

Publication Number Publication Date
CN1642922A CN1642922A (zh) 2005-07-20
CN100369899C true CN100369899C (zh) 2008-02-20

Family

ID=27763684

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038058731A Expired - Fee Related CN100369899C (zh) 2002-03-11 2003-03-07 具有抗癌活性的取代的吲唑

Country Status (29)

Country Link
US (2) US6858638B2 (enExample)
EP (1) EP1487803A1 (enExample)
JP (1) JP4643910B2 (enExample)
KR (1) KR20040091128A (enExample)
CN (1) CN100369899C (enExample)
AR (1) AR038914A1 (enExample)
AU (1) AU2003242808B2 (enExample)
BR (1) BR0308339A (enExample)
CA (1) CA2478540A1 (enExample)
EC (1) ECSP045286A (enExample)
FR (1) FR2836914B1 (enExample)
GT (1) GT200300031A (enExample)
HN (1) HN2003000094A (enExample)
HR (1) HRP20040825A2 (enExample)
IL (2) IL163805A0 (enExample)
MA (1) MA27176A1 (enExample)
MX (1) MXPA04008446A (enExample)
NO (1) NO20044261L (enExample)
OA (1) OA12784A (enExample)
PA (1) PA8566701A1 (enExample)
PE (1) PE20040071A1 (enExample)
PL (1) PL372389A1 (enExample)
RU (1) RU2004130280A (enExample)
SV (1) SV2003001493A (enExample)
TN (1) TNSN04175A1 (enExample)
TW (1) TW200303863A (enExample)
UY (1) UY27712A1 (enExample)
WO (1) WO2003078402A1 (enExample)
ZA (1) ZA200406730B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102247361A (zh) * 2010-05-20 2011-11-23 中国医学科学院药物研究所 5-硝基-1氢-吲唑-3-腈在制备药物中的应用

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
GB0218625D0 (en) * 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
AU2003286711A1 (en) 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2005014554A1 (en) * 2003-08-08 2005-02-17 Astex Therapeutics Limited 1h-indazole-3-carboxamide compounds as mapkap kinase modulators
FR2864084B1 (fr) * 2003-12-17 2006-02-10 Aventis Pharma Sa Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
GB0330042D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
PT1797042E (pt) * 2004-09-29 2009-02-12 Hoffmann La Roche Derivados de indozolona como inibidores de 11b-hsd1
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
SE0402763D0 (sv) * 2004-11-11 2004-11-11 Astrazeneca Ab Nitro indazole derivatives
SE0402762D0 (sv) * 2004-11-11 2004-11-11 Astrazeneca Ab Indazole sulphonamide derivatives
CA2620257A1 (en) * 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
RU2442777C2 (ru) 2006-01-31 2012-02-20 Эррэй Биофарма Инк. Ингибиторы киназ и способы их применения
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
JP2010505961A (ja) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
WO2008063888A2 (en) * 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
FR2917735B1 (fr) * 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
WO2009012312A1 (en) 2007-07-16 2009-01-22 Abbott Laboratories Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
BR122019016429B1 (pt) * 2009-05-26 2020-03-24 Abbvie Ireland Unlimited Company Compostos inibidores da atividade de proteínas bcl-2 antiapoptótica e composição farmacêutica compreendendo ditos compostos
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2011050245A1 (en) * 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
ES2699205T3 (es) 2010-10-29 2019-02-07 Abbvie Inc Dispersiones sólidas que contienen un agente que induce la apoptosis
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
NZ708508A (en) 2010-11-23 2016-06-24 Abbvie Bahamas Ltd Methods of treatment using selective bcl-2 inhibitors
AU2011332043C1 (en) 2010-11-23 2016-11-10 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
RU2719446C2 (ru) * 2014-11-03 2020-04-17 Айомет Фарма Лтд Фармацевтическое соединение
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
CA3070112A1 (en) * 2017-07-21 2019-01-24 Kadmon Corporation, Llc Inhibitors of rho associated coiled-coil containing protein kinase
CN111479805B (zh) 2017-08-29 2024-08-13 罗格斯新泽西州立大学 治疗性吲唑
CN118715205A (zh) * 2022-01-12 2024-09-27 艾福姆德尤股份有限公司 用于治疗与sting活性相关的病症的化合物和组合物
JP2025509180A (ja) 2022-03-04 2025-04-11 上海瓔黎薬業有限公司 五員ヘテロアリール環構造含有化合物、その医薬組成物及び使用
CN114605329B (zh) * 2022-03-28 2024-01-26 河南中医药大学 取代的吲唑甲酰胺或取代的氮杂吲唑甲酰胺类flt3抑制剂及其用途
AU2023415105A1 (en) 2022-12-30 2025-07-17 Avicenna Biosciences, Inc. Azaindole rock inhibitors
WO2025117661A1 (en) * 2023-11-28 2025-06-05 Quantx Biosciences Us, Inc. Bicyclic heteroaryl compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6225747A (ja) * 1985-07-26 1987-02-03 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
WO1998005315A1 (en) * 1996-07-19 1998-02-12 Tularik, Inc. Pentafluorobenzenesulfonamides and analogs
WO1999064004A1 (en) * 1998-06-08 1999-12-16 Bristol-Myers Squibb Company QUINAZOLINONE INHIBITORS OF cGMP PHOSPHODIESTERASE
WO2000073264A1 (en) * 1999-05-28 2000-12-07 Abbott Laboratories Cell proliferation inhibitors
WO2002010137A2 (en) * 2000-07-31 2002-02-07 Signal Pharmaceuticals, Inc. Indazole derivatives as jnk inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS514505Y2 (enExample) 1971-02-13 1976-02-07
JP3421349B2 (ja) 1996-02-22 2003-06-30 テュラリク インコーポレイテッド ペンタフルオロベンゼンスルホンアミドおよび類縁体
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
WO2000027627A1 (en) 1998-11-12 2000-05-18 Eli Lilly And Company Aryloxime linkers in the solid-phase synthesis of 3-aminobenzisoxazoles
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
KR100423899B1 (ko) * 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
CA2440842A1 (en) * 2001-04-16 2002-10-24 Eisai Co., Ltd. Novel 1h-indazole compounds
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
EP1401831A1 (en) * 2001-07-03 2004-03-31 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
US7101884B2 (en) 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
FR2836915B1 (fr) * 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6225747A (ja) * 1985-07-26 1987-02-03 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
WO1998005315A1 (en) * 1996-07-19 1998-02-12 Tularik, Inc. Pentafluorobenzenesulfonamides and analogs
WO1999064004A1 (en) * 1998-06-08 1999-12-16 Bristol-Myers Squibb Company QUINAZOLINONE INHIBITORS OF cGMP PHOSPHODIESTERASE
WO2000073264A1 (en) * 1999-05-28 2000-12-07 Abbott Laboratories Cell proliferation inhibitors
WO2002010137A2 (en) * 2000-07-31 2002-02-07 Signal Pharmaceuticals, Inc. Indazole derivatives as jnk inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102247361A (zh) * 2010-05-20 2011-11-23 中国医学科学院药物研究所 5-硝基-1氢-吲唑-3-腈在制备药物中的应用
CN102247361B (zh) * 2010-05-20 2015-04-29 中国医学科学院药物研究所 5-硝基-1氢-吲唑-3-腈在制备药物中的应用

Also Published As

Publication number Publication date
OA12784A (fr) 2006-07-10
BR0308339A (pt) 2005-02-01
US20040106667A1 (en) 2004-06-03
PE20040071A1 (es) 2004-02-13
US20050059722A1 (en) 2005-03-17
NO20044261L (no) 2004-11-25
KR20040091128A (ko) 2004-10-27
ZA200406730B (en) 2005-08-24
AU2003242808A1 (en) 2003-09-29
FR2836914B1 (fr) 2008-03-14
IL163805A0 (en) 2005-12-18
SV2003001493A (es) 2003-07-10
PA8566701A1 (es) 2003-12-10
US7473701B2 (en) 2009-01-06
EP1487803A1 (fr) 2004-12-22
HRP20040825A2 (en) 2005-06-30
JP4643910B2 (ja) 2011-03-02
MXPA04008446A (es) 2004-12-06
GT200300031A (es) 2006-05-26
CN1642922A (zh) 2005-07-20
ECSP045286A (es) 2004-10-26
PL372389A1 (en) 2005-07-25
AR038914A1 (es) 2005-02-02
TW200303863A (en) 2003-09-16
UY27712A1 (es) 2003-09-30
WO2003078402A1 (fr) 2003-09-25
IL163805A (en) 2009-08-03
HN2003000094A (es) 2003-12-15
RU2004130280A (ru) 2005-06-27
CA2478540A1 (fr) 2003-09-25
US6858638B2 (en) 2005-02-22
TNSN04175A1 (fr) 2007-03-12
JP2005533004A (ja) 2005-11-04
MA27176A1 (fr) 2005-01-03
AU2003242808B2 (en) 2008-09-18
FR2836914A1 (fr) 2003-09-12

Similar Documents

Publication Publication Date Title
CN100369899C (zh) 具有抗癌活性的取代的吲唑
JP5676650B2 (ja) プロテインキナーゼ阻害活性を有するチエノ［３，２−ｄ］ピリミジン誘導体
AU2005259139B2 (en) Substituted indazoles, compositions containing same, preparation and use
JP7337951B2 (ja) 癌を治療するための窒素含有芳香族ヘテロ環アミド誘導体
KR100928602B1 (ko) 티로신 키나제 억제제로서 적합한 시클릭 디아릴 우레아
JP2005529954A (ja) 化学プロセス
CZ304059B6 (cs) Deriváty pyrimidinu a farmaceutický prostredek
US20100016307A1 (en) Novel compounds
WO2021138392A1 (en) Aminopyrimidine compounds
CN107021937B (zh) 苯并噻唑甲酰胺类化合物及其应用
JP2005501826A (ja) 置換イソインドールおよびそれらの使用
WO2004111036A1 (en) 4- (heterocyclyl- fused phenyl)- 3- (phenyl or pyrid -2- yl) pyrazoles as inhibitors of the alk-5- receptor
CA3136535A1 (en) Benzo- and pyrido-pyrazoles as protein kinase inhibitors
KR20070113214A (ko) 히드라지노카르보닐-티에노[2,3-ｃ]피라졸, 제조 방법,그를 함유하는 조성물 및 용도
WO2023031308A1 (en) Ccr2 inhibitors
JP2007511571A (ja) 癌およびアテローム性動脈硬化症のような疾患の治療において有用な置換イソキノリン
KR100744826B1 (ko) 이미다졸기가 치환된 퀴놀리논 유도체
HK1142592A1 (en) Alkynylpyrimidines as tie2 kinase inhibitors
HK1142592B (en) Alkynylpyrimidines as tie2 kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1075249

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1075249

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080220

Termination date: 20110307